Targeted therapies for treatment of non‐small cell lung cancer—recent advances and future perspectives
J Minguet, KH Smith, P Bramlage - International journal of …, 2016 - Wiley Online Library
Non‐small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor
prognosis once the disease has progressed past the point at which surgery is a viable …
prognosis once the disease has progressed past the point at which surgery is a viable …
Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
ZY Xu, JL Li - OncoTargets and therapy, 2019 - Taylor & Francis
The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the
epidermal growth factor receptor (EGFR) has revolutionized the management of non-small …
epidermal growth factor receptor (EGFR) has revolutionized the management of non-small …
[HTML][HTML] KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/MAPK pathway in an m6A-dependent manner
X Lin, R Ye, Z Li, B Zhang, Y Huang, J Du… - Drug Resistance …, 2023 - Elsevier
Non-small cell lung cancer is the leading cause of cancer related mortality worldwide, and
lung adenocarcinoma (LUAD) is one of the most common subtypes. The role of N6 …
lung adenocarcinoma (LUAD) is one of the most common subtypes. The role of N6 …
Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
P Chen, HP Huang, Y Wang, J Jin, WG Long… - Journal of Experimental …, 2019 - Springer
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
being wildly used as target therapy in non-small-cell lung cancer (NSCLC). However …
being wildly used as target therapy in non-small-cell lung cancer (NSCLC). However …
Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR
Non-small-cell lung cancer (NSCLC) is associated with diverse genetic alterations including
mutation of epidermal growth factor receptor (EGFR). Isoliquiritigenin (ILQ), a chalcone …
mutation of epidermal growth factor receptor (EGFR). Isoliquiritigenin (ILQ), a chalcone …
Glycyrrhetinic acid induces G1‑phase cell cycle arrest in human non‑small cell lung cancer cells through endoplasmic reticulum stress pathway
J Zhu, M Chen, N Chen, A Ma… - International …, 2015 - spandidos-publications.com
Glycyrrhetinic acid (GA) is a natural compound extracted from liquorice, which is often used
in traditional Chinese medicine. The purpose of the present study was to investigate the …
in traditional Chinese medicine. The purpose of the present study was to investigate the …
[HTML][HTML] Evidence, mechanism, and clinical relevance of the transdifferentiation from lung adenocarcinoma to squamous cell carcinoma
Lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC) are two distinct subtypes
of non–small-cell lung carcinoma. Interestingly, approximately 4% to 9% of human non …
of non–small-cell lung carcinoma. Interestingly, approximately 4% to 9% of human non …
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the …
X Wang, D Goldstein, PJ Crowe… - OncoTargets and …, 2016 - Taylor & Francis
Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor
(EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non …
(EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non …
Role of rebiopsy in relapsed non‐small cell lung cancer for directing oncology treatments
AP Jekunen - Journal of oncology, 2015 - Wiley Online Library
Background. Currently, few rebiopsies are performed in relapses of advanced non‐small
cell lung cancer. They are not customary in clinical practice of lung cancer. However, it is not …
cell lung cancer. They are not customary in clinical practice of lung cancer. However, it is not …
Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer …
S Zhang, L Zhu, B Xia, E Chen, Q Zhao, X Zhang… - Cancer …, 2018 - Springer
Introduction Plasma circulating tumor DNA (ctDNA) is an ideal approach to detecting the
epidermal growth factor receptor (EGFR) T790M mutation, which is a major mechanism of …
epidermal growth factor receptor (EGFR) T790M mutation, which is a major mechanism of …